Compare
GeneDx Holdings Corp. vs Omada Health, Inc. vs U S Physical Therapy Inc vs Pennant Group, Inc.
| Latest fiscal year | GeneDx Holdings Corp. WGS | Omada Health, Inc. OMDA | U S Physical Therapy Inc USPH | Pennant Group, Inc. PNTG |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $427.54M | $260.21M | $780.99M | $947.71M |
| Revenue growth (YoY) | +40.0% | +53.2% | +16.3% | +36.3% |
| Gross margin | 69.7% | 65.7% | 19.2% | n/a |
| Operating margin | -3.1% | -4.6% | 11.1% | 5.5% |
| Net margin | -4.9% | -4.9% | 5.1% | 3.1% |
| Net income | -$21.02M | -$12.78M | $39.58M | $29.58M |
| EPS (Diluted) | -$0.73 | -$0.35 | $1.42 | $0.84 |
| Operating cash flow | $33.28M | $18.25M | $75.06M | $48.29M |
| Free cash flow | $14.26M | $16.93M | $60.99M | $36.26M |
| Cash & equivalents | $105.00M | $222.04M | $35.57M | n/a |
| Total assets | $523.71M | $305.41M | $1.20B | $968.18M |
| Total liabilities | $215.53M | $75.73M | $433.81M | $593.93M |
| Shareholders' equity | $308.18M | $229.68M | $476.89M | $374.25M |
| Return on year-end equity | -6.8% | -5.6% | 8.3% | 7.9% |
| Shares outstanding | 29.25M | 58.43M | n/a | 34.63M |
Revenue, most recent five fiscal years
| Fiscal year | GeneDx Holdings Corp. | Omada Health, Inc. | U S Physical Therapy Inc | Pennant Group, Inc. |
|---|---|---|---|---|
| Latest | $427.54M Ended 2025-12-31 | $260.21M Ended 2025-12-31 | $780.99M Ended 2025-12-31 | $947.71M Ended 2025-12-31 |
| 1 year earlier | $305.45M Ended 2024-12-31 | $169.80M Ended 2024-12-31 | $671.35M Ended 2024-12-31 | $695.24M Ended 2024-12-31 |
| 2 years earlier | $202.57M Ended 2023-12-31 | $122.78M Ended 2023-12-31 | $604.80M Ended 2023-12-31 | $544.89M Ended 2023-12-31 |
| 3 years earlier | $234.69M Ended 2022-12-31 | n/a | $553.14M Ended 2022-12-31 | $473.24M Ended 2022-12-31 |
| 4 years earlier | $212.19M Ended 2021-12-31 | n/a | $495.02M Ended 2021-12-31 | $439.69M Ended 2021-12-31 |